Literature DB >> 16044456

Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.

Clarence C K Lam1, Edmond S K Ma, Yok-Lam Kwong.   

Abstract

A 70-year-old man with B-cell chronic lymphocytic leukemia (CLL) received single-agent treatment with the purine analogue fludarabine, which led to complete remission. After 8 years, he presented with pancytopenia. Marrow examination showed acute myeloid leukemia (AML) with trilineage myelodysplasia (MDS). Cytogenetic analysis showed an unbalanced der(1;7)(p10;q10) that resulted effectively in deletion 7q; confirming the diagnosis of therapy-related AML (t-AML). No residual CLL was present. Together with previous reports of secondary cancers after fludarabine treatment and the association of monosomy 7/7q- with another purine analogue azathioprine, results suggest that t-AML might develop after fludarabine therapy. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044456     DOI: 10.1002/ajh.20340

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Treatment-related acute myeloid leukemia in a chronic lymphocytic leukemia patient: role of fludarabine?

Authors:  Smith Giri; Vijaya Raj Bhatt; Sumesh Khanal; Apar Kishor Ganti
Journal:  Ther Adv Hematol       Date:  2015-04

2.  Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2.

Authors:  C Pepper; J G Mahdi; A G S Buggins; S Hewamana; E Walsby; E Mahdi; A Al-Haza'a; A J Mahdi; T T Lin; L Pearce; L Morgan; I D Bowen; P Brennan; C Fegan
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

3.  Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Bercedis L Peterson; John G Gribben; Vicki A Morrison; Kanti R Rai; Richard A Larson; John C Byrd
Journal:  J Clin Oncol       Date:  2011-02-14       Impact factor: 44.544

4.  Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results.

Authors:  Harinder Gill; Chor-Sang Chim; Wing-Yan Au; Florence Loong; Eric Tse; Anskar Y H Leung; Yok-Lam Kwong
Journal:  Ann Hematol       Date:  2011-04-08       Impact factor: 3.673

5.  Second cancer incidence in CLL patients receiving BTK inhibitors.

Authors:  David A Bond; Ying Huang; James L Fisher; Amy S Ruppert; Dwight H Owen; Erin M Bertino; Kerry A Rogers; Seema A Bhat; Michael R Grever; Samantha M Jaglowski; Kami J Maddocks; John C Byrd; Jennifer A Woyach
Journal:  Leukemia       Date:  2020-07-23       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.